Stryker / Cerus merger inquiry
The CMA investigated and cleared the anticipated acquisition by Stryker Corporation of Cerus Endovascular Limited
Statutory timetable
| Phase 1 date | Action |
|---|---|
| 19 May 2023 | Decision published |
| 17 April 2023 | Decision announced |
| 23 February 2023 to 9 March 2023 | Invitation to comment |
| 23 February 2023 | Launch of merger inquiry |
Phase 1
CMA Clearance decision
17 April 2023: The CMA has cleared the anticipated acquisition by Stryker Corporation of Cerus Endovascular Limited.
- (19.5.23)
Launch of merger inquiry
23 February 2023: The CMA announced the launch of its merger inquiry by notice to the parties.
- (23.2.23)
Invitation to comment: closed on 9 March 2023
23 February 2023: The CMA is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
To assist it with this assessment, the CMA invites comments on the transaction from any interested party.
These comments should be provided by the deadline set out above to:
Contact
Please send written representations about any competition or public interest to:
- Georgia Zele, [email protected]
- Gulalay Hammad, [email protected]
Updates to this page
Published 23 February 2023Last updated 19 May 2023 + show all updates
-
Full text decision published.
-
Case closed.
-
First published.